nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—JAK3—hematologic cancer	0.115	0.31	CbGaD
Erlotinib—FLT3—hematologic cancer	0.0871	0.235	CbGaD
Erlotinib—ABL2—hematologic cancer	0.0777	0.21	CbGaD
Erlotinib—ABL1—hematologic cancer	0.0347	0.0936	CbGaD
Erlotinib—PIP4K2C—Imatinib—hematologic cancer	0.0318	0.0815	CbGbCtD
Erlotinib—JAK3—Ruxolitinib—hematologic cancer	0.0299	0.0767	CbGbCtD
Erlotinib—UGT1A1—hematologic cancer	0.0274	0.074	CbGaD
Erlotinib—LTK—Ruxolitinib—hematologic cancer	0.0238	0.061	CbGbCtD
Erlotinib—HIPK4—Imatinib—hematologic cancer	0.0161	0.0414	CbGbCtD
Erlotinib—ABCG2—hematologic cancer	0.0154	0.0416	CbGaD
Erlotinib—EPHA6—Nilotinib—hematologic cancer	0.0147	0.0376	CbGbCtD
Erlotinib—ABL2—Imatinib—hematologic cancer	0.0145	0.0372	CbGbCtD
Erlotinib—ABL2—Nilotinib—hematologic cancer	0.0132	0.0338	CbGbCtD
Erlotinib—CYP1B1—Procarbazine—hematologic cancer	0.0123	0.0314	CbGbCtD
Erlotinib—MAP2K5—Nilotinib—hematologic cancer	0.012	0.0307	CbGbCtD
Erlotinib—ABL2—Dasatinib—hematologic cancer	0.0117	0.0299	CbGbCtD
Erlotinib—MAP3K19—Ruxolitinib—hematologic cancer	0.0114	0.0293	CbGbCtD
Erlotinib—MAP2K5—Dasatinib—hematologic cancer	0.0106	0.0272	CbGbCtD
Erlotinib—ABL1—Imatinib—hematologic cancer	0.0105	0.0269	CbGbCtD
Erlotinib—MAP3K19—Dasatinib—hematologic cancer	0.00975	0.025	CbGbCtD
Erlotinib—ABL1—Nilotinib—hematologic cancer	0.00953	0.0244	CbGbCtD
Erlotinib—ABL1—Dasatinib—hematologic cancer	0.00842	0.0216	CbGbCtD
Erlotinib—ALB—hematologic cancer	0.00672	0.0181	CbGaD
Erlotinib—CYP1B1—Daunorubicin—hematologic cancer	0.00658	0.0169	CbGbCtD
Erlotinib—ABCB1—hematologic cancer	0.00641	0.0173	CbGaD
Erlotinib—ABCG2—Clofarabine—hematologic cancer	0.00533	0.0137	CbGbCtD
Erlotinib—CYP1B1—Dasatinib—hematologic cancer	0.00405	0.0104	CbGbCtD
Erlotinib—CYP1B1—Mitoxantrone—hematologic cancer	0.004	0.0102	CbGbCtD
Erlotinib—UGT1A1—Nilotinib—hematologic cancer	0.00396	0.0101	CbGbCtD
Erlotinib—ORM1—Imatinib—hematologic cancer	0.00392	0.0101	CbGbCtD
Erlotinib—CYP1A2—Anagrelide—hematologic cancer	0.00317	0.00813	CbGbCtD
Erlotinib—CYP1A1—Methoxsalen—hematologic cancer	0.00317	0.00813	CbGbCtD
Erlotinib—ABCG2—Daunorubicin—hematologic cancer	0.00313	0.00801	CbGbCtD
Erlotinib—CYP1A1—Bortezomib—hematologic cancer	0.00302	0.00773	CbGbCtD
Erlotinib—CYP1A1—Daunorubicin—hematologic cancer	0.00289	0.0074	CbGbCtD
Erlotinib—UGT1A1—Irinotecan—hematologic cancer	0.00272	0.00697	CbGbCtD
Erlotinib—ABCG2—Teniposide—hematologic cancer	0.00272	0.00696	CbGbCtD
Erlotinib—CYP1A1—Thalidomide—hematologic cancer	0.00263	0.00674	CbGbCtD
Erlotinib—ABCG2—Cladribine—hematologic cancer	0.00261	0.00668	CbGbCtD
Erlotinib—ABCG2—Imatinib—hematologic cancer	0.0024	0.00614	CbGbCtD
Erlotinib—CYP1A1—Dacarbazine—hematologic cancer	0.00226	0.00579	CbGbCtD
Erlotinib—UGT1A1—Etoposide—hematologic cancer	0.00218	0.00558	CbGbCtD
Erlotinib—ABCG2—Nilotinib—hematologic cancer	0.00218	0.00558	CbGbCtD
Erlotinib—CYP1B1—Dexamethasone—hematologic cancer	0.00207	0.00531	CbGbCtD
Erlotinib—ABCG2—Dasatinib—hematologic cancer	0.00192	0.00493	CbGbCtD
Erlotinib—ABCB1—Lenalidomide—hematologic cancer	0.00192	0.00493	CbGbCtD
Erlotinib—ABCG2—Mitoxantrone—hematologic cancer	0.0019	0.00487	CbGbCtD
Erlotinib—CYP1A1—Dasatinib—hematologic cancer	0.00178	0.00455	CbGbCtD
Erlotinib—CYP2C8—Bortezomib—hematologic cancer	0.00174	0.00446	CbGbCtD
Erlotinib—CYP3A5—Daunorubicin—hematologic cancer	0.00173	0.00444	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—hematologic cancer	0.00172	0.00441	CbGbCtD
Erlotinib—CYP2D6—Lomustine—hematologic cancer	0.00168	0.00432	CbGbCtD
Erlotinib—CYP1A2—Carmustine—hematologic cancer	0.00167	0.00427	CbGbCtD
Erlotinib—ALB—Imatinib—hematologic cancer	0.00165	0.00423	CbGbCtD
Erlotinib—CYP3A5—Thalidomide—hematologic cancer	0.00158	0.00404	CbGbCtD
Erlotinib—CYP3A5—Teniposide—hematologic cancer	0.00151	0.00386	CbGbCtD
Erlotinib—CYP2D6—Idarubicin—hematologic cancer	0.0015	0.00385	CbGbCtD
Erlotinib—ABCG2—Irinotecan—hematologic cancer	0.0015	0.00383	CbGbCtD
Erlotinib—CYP1A2—Methoxsalen—hematologic cancer	0.00142	0.00363	CbGbCtD
Erlotinib—CYP3A5—Ifosfamide—hematologic cancer	0.00139	0.00356	CbGbCtD
Erlotinib—CYP1A2—Bortezomib—hematologic cancer	0.00135	0.00346	CbGbCtD
Erlotinib—CYP2C8—Ifosfamide—hematologic cancer	0.00134	0.00342	CbGbCtD
Erlotinib—CYP3A5—Imatinib—hematologic cancer	0.00133	0.0034	CbGbCtD
Erlotinib—ABCG2—Vincristine—hematologic cancer	0.00131	0.00335	CbGbCtD
Erlotinib—CYP1A2—Daunorubicin—hematologic cancer	0.00129	0.0033	CbGbCtD
Erlotinib—CYP2D6—Hydroxyurea—hematologic cancer	0.00128	0.00327	CbGbCtD
Erlotinib—CYP1A2—Alitretinoin—hematologic cancer	0.00126	0.00324	CbGbCtD
Erlotinib—ABCG2—Cisplatin—hematologic cancer	0.00122	0.00313	CbGbCtD
Erlotinib—ABCG2—Etoposide—hematologic cancer	0.0012	0.00307	CbGbCtD
Erlotinib—CYP1A2—Thalidomide—hematologic cancer	0.00117	0.00301	CbGbCtD
Erlotinib—CYP2C8—Nilotinib—hematologic cancer	0.00116	0.00297	CbGbCtD
Erlotinib—CYP3A4—Bexarotene—hematologic cancer	0.00115	0.00295	CbGbCtD
Erlotinib—ABCB1—Daunorubicin—hematologic cancer	0.00113	0.00289	CbGbCtD
Erlotinib—CYP2D6—Bortezomib—hematologic cancer	0.00111	0.00285	CbGbCtD
Erlotinib—ABCB1—Alitretinoin—hematologic cancer	0.0011	0.00283	CbGbCtD
Erlotinib—ALB—Prednisone—hematologic cancer	0.00109	0.00279	CbGbCtD
Erlotinib—CYP3A4—Busulfan—hematologic cancer	0.00107	0.00275	CbGbCtD
Erlotinib—CYP3A4—Lomustine—hematologic cancer	0.00107	0.00275	CbGbCtD
Erlotinib—CYP3A5—Dasatinib—hematologic cancer	0.00107	0.00273	CbGbCtD
Erlotinib—ALB—Irinotecan—hematologic cancer	0.00103	0.00264	CbGbCtD
Erlotinib—CYP1A2—Dacarbazine—hematologic cancer	0.00101	0.00259	CbGbCtD
Erlotinib—CYP1A2—Imatinib—hematologic cancer	0.000988	0.00253	CbGbCtD
Erlotinib—ABCG2—Dexamethasone—hematologic cancer	0.000985	0.00253	CbGbCtD
Erlotinib—CYP3A4—Thiotepa—hematologic cancer	0.000955	0.00245	CbGbCtD
Erlotinib—CYP1A1—Dexamethasone—hematologic cancer	0.000909	0.00233	CbGbCtD
Erlotinib—JAK3—hematopoietic system—hematologic cancer	0.000897	0.0232	CbGeAlD
Erlotinib—ABCB1—Imatinib—hematologic cancer	0.000864	0.00221	CbGbCtD
Erlotinib—HIPK4—gonad—hematologic cancer	0.000863	0.0223	CbGeAlD
Erlotinib—CYP3A5—Irinotecan—hematologic cancer	0.000829	0.00212	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—hematologic cancer	0.000817	0.00209	CbGbCtD
Erlotinib—CYP2D6—Imatinib—hematologic cancer	0.000814	0.00209	CbGbCtD
Erlotinib—CYP1A2—Dasatinib—hematologic cancer	0.000793	0.00203	CbGbCtD
Erlotinib—ABCG2—Methotrexate—hematologic cancer	0.000792	0.00203	CbGbCtD
Erlotinib—ABCB1—Nilotinib—hematologic cancer	0.000785	0.00201	CbGbCtD
Erlotinib—ABCB1—Vinorelbine—hematologic cancer	0.000778	0.00199	CbGbCtD
Erlotinib—CYP3A4—Methoxsalen—hematologic cancer	0.000743	0.0019	CbGbCtD
Erlotinib—CYP2D6—Nilotinib—hematologic cancer	0.00074	0.0019	CbGbCtD
Erlotinib—AURKC—gonad—hematologic cancer	0.000737	0.019	CbGeAlD
Erlotinib—CYP2D6—Vinorelbine—hematologic cancer	0.000733	0.00188	CbGbCtD
Erlotinib—CYP3A5—Vincristine—hematologic cancer	0.000725	0.00186	CbGbCtD
Erlotinib—FLT3—hematopoietic system—hematologic cancer	0.000708	0.0183	CbGeAlD
Erlotinib—CYP3A4—Bortezomib—hematologic cancer	0.000706	0.00181	CbGbCtD
Erlotinib—ABCB1—Dasatinib—hematologic cancer	0.000694	0.00178	CbGbCtD
Erlotinib—ABCB1—Mitoxantrone—hematologic cancer	0.000685	0.00176	CbGbCtD
Erlotinib—EPHA6—gonad—hematologic cancer	0.000682	0.0176	CbGeAlD
Erlotinib—CYP3A4—Daunorubicin—hematologic cancer	0.000676	0.00173	CbGbCtD
Erlotinib—CYP3A5—Etoposide—hematologic cancer	0.000664	0.0017	CbGbCtD
Erlotinib—LTK—lung—hematologic cancer	0.000652	0.0168	CbGeAlD
Erlotinib—CYP2C8—Etoposide—hematologic cancer	0.000638	0.00164	CbGbCtD
Erlotinib—HIPK4—testis—hematologic cancer	0.000622	0.0161	CbGeAlD
Erlotinib—LTK—testis—hematologic cancer	0.000615	0.0159	CbGeAlD
Erlotinib—ABCB1—Betamethasone—hematologic cancer	0.000611	0.00157	CbGbCtD
Erlotinib—ULK3—hematopoietic system—hematologic cancer	0.000611	0.0158	CbGeAlD
Erlotinib—ABCB1—Gemcitabine—hematologic cancer	0.000605	0.00155	CbGbCtD
Erlotinib—ABCB1—Prednisolone—hematologic cancer	0.000603	0.00154	CbGbCtD
Erlotinib—CYP3A4—Cytarabine—hematologic cancer	0.000596	0.00153	CbGbCtD
Erlotinib—JAK3—blood—hematologic cancer	0.000595	0.0154	CbGeAlD
Erlotinib—CYP3A4—Teniposide—hematologic cancer	0.000587	0.0015	CbGbCtD
Erlotinib—MKNK1—hematopoietic system—hematologic cancer	0.000575	0.0148	CbGeAlD
Erlotinib—ABCB1—Prednisone—hematologic cancer	0.000569	0.00146	CbGbCtD
Erlotinib—CYP3A5—Dexamethasone—hematologic cancer	0.000546	0.0014	CbGbCtD
Erlotinib—TNK1—blood—hematologic cancer	0.000546	0.0141	CbGeAlD
Erlotinib—ALB—Methotrexate—hematologic cancer	0.000546	0.0014	CbGbCtD
Erlotinib—CYP3A4—Ifosfamide—hematologic cancer	0.000542	0.00139	CbGbCtD
Erlotinib—ABCB1—Irinotecan—hematologic cancer	0.00054	0.00138	CbGbCtD
Erlotinib—FLT3—gonad—hematologic cancer	0.000538	0.0139	CbGeAlD
Erlotinib—AURKC—testis—hematologic cancer	0.000531	0.0137	CbGeAlD
Erlotinib—CYP2C8—Dexamethasone—hematologic cancer	0.000525	0.00135	CbGbCtD
Erlotinib—JAK3—lung—hematologic cancer	0.000521	0.0135	CbGeAlD
Erlotinib—CYP3A4—Imatinib—hematologic cancer	0.000518	0.00133	CbGbCtD
Erlotinib—CYP1A2—Etoposide—hematologic cancer	0.000494	0.00127	CbGbCtD
Erlotinib—JAK3—testis—hematologic cancer	0.000492	0.0127	CbGeAlD
Erlotinib—EPHA6—testis—hematologic cancer	0.000492	0.0127	CbGeAlD
Erlotinib—CYP3A4—Ruxolitinib—hematologic cancer	0.000487	0.00125	CbGbCtD
Erlotinib—PIP4K2C—gonad—hematologic cancer	0.000486	0.0126	CbGeAlD
Erlotinib—ABCB1—Vinblastine—hematologic cancer	0.00048	0.00123	CbGbCtD
Erlotinib—TNK1—lung—hematologic cancer	0.000479	0.0124	CbGeAlD
Erlotinib—MAP3K19—lung—hematologic cancer	0.000474	0.0122	CbGeAlD
Erlotinib—STK10—hematopoietic system—hematologic cancer	0.000473	0.0122	CbGeAlD
Erlotinib—ABCB1—Vincristine—hematologic cancer	0.000472	0.00121	CbGbCtD
Erlotinib—CYP3A4—Nilotinib—hematologic cancer	0.00047	0.00121	CbGbCtD
Erlotinib—FLT3—blood—hematologic cancer	0.000469	0.0121	CbGeAlD
Erlotinib—CYP3A4—Vinorelbine—hematologic cancer	0.000466	0.0012	CbGbCtD
Erlotinib—Vandetanib—FLT3—hematologic cancer	0.000465	0.161	CrCbGaD
Erlotinib—ULK3—gonad—hematologic cancer	0.000464	0.012	CbGeAlD
Erlotinib—FLT3—bone marrow—hematologic cancer	0.000454	0.0117	CbGeAlD
Erlotinib—CYP2D6—Vinblastine—hematologic cancer	0.000452	0.00116	CbGbCtD
Erlotinib—TNK1—testis—hematologic cancer	0.000451	0.0117	CbGeAlD
Erlotinib—ABL2—blood—hematologic cancer	0.000448	0.0116	CbGeAlD
Erlotinib—MAP3K19—testis—hematologic cancer	0.000447	0.0115	CbGeAlD
Erlotinib—UGT1A1—hematopoietic system—hematologic cancer	0.000447	0.0115	CbGeAlD
Erlotinib—LTK—lymph node—hematologic cancer	0.000446	0.0115	CbGeAlD
Erlotinib—ABCB1—Cisplatin—hematologic cancer	0.00044	0.00113	CbGbCtD
Erlotinib—MKNK1—gonad—hematologic cancer	0.000437	0.0113	CbGeAlD
Erlotinib—ABCB1—Etoposide—hematologic cancer	0.000432	0.00111	CbGbCtD
Erlotinib—CYP3A4—Triamcinolone—hematologic cancer	0.000427	0.00109	CbGbCtD
Erlotinib—PIP4K2C—blood—hematologic cancer	0.000424	0.0109	CbGeAlD
Erlotinib—CYP3A4—Dasatinib—hematologic cancer	0.000416	0.00107	CbGbCtD
Erlotinib—Vandetanib—ABL2—hematologic cancer	0.000415	0.144	CrCbGaD
Erlotinib—FLT3—lung—hematologic cancer	0.000411	0.0106	CbGeAlD
Erlotinib—CYP3A4—Mitoxantrone—hematologic cancer	0.000411	0.00105	CbGbCtD
Erlotinib—PIP4K2C—bone marrow—hematologic cancer	0.00041	0.0106	CbGeAlD
Erlotinib—ULK3—blood—hematologic cancer	0.000404	0.0104	CbGeAlD
Erlotinib—Vandetanib—LCK—hematologic cancer	0.000396	0.137	CrCbGaD
Erlotinib—ABL2—lung—hematologic cancer	0.000393	0.0101	CbGeAlD
Erlotinib—ULK3—bone marrow—hematologic cancer	0.000391	0.0101	CbGeAlD
Erlotinib—FLT3—testis—hematologic cancer	0.000388	0.01	CbGeAlD
Erlotinib—AURKC—lymph node—hematologic cancer	0.000385	0.00994	CbGeAlD
Erlotinib—EGFR—lung—hematologic cancer	0.000383	0.00989	CbGeAlD
Erlotinib—MKNK1—blood—hematologic cancer	0.000381	0.00983	CbGeAlD
Erlotinib—PIP4K2C—lung—hematologic cancer	0.000371	0.00959	CbGeAlD
Erlotinib—ABL2—testis—hematologic cancer	0.00037	0.00956	CbGeAlD
Erlotinib—MKNK1—bone marrow—hematologic cancer	0.000368	0.00951	CbGeAlD
Erlotinib—CYP3A4—Betamethasone—hematologic cancer	0.000366	0.000938	CbGbCtD
Erlotinib—EGFR—testis—hematologic cancer	0.000361	0.00934	CbGeAlD
Erlotinib—CYP3A4—Prednisolone—hematologic cancer	0.000361	0.000925	CbGbCtD
Erlotinib—SLK—blood—hematologic cancer	0.000361	0.00931	CbGeAlD
Erlotinib—STK10—gonad—hematologic cancer	0.00036	0.00929	CbGeAlD
Erlotinib—JAK3—lymph node—hematologic cancer	0.000356	0.00921	CbGeAlD
Erlotinib—ABCB1—Dexamethasone—hematologic cancer	0.000355	0.000911	CbGbCtD
Erlotinib—ULK3—lung—hematologic cancer	0.000355	0.00916	CbGeAlD
Erlotinib—Vandetanib—FGR—hematologic cancer	0.000353	0.122	CrCbGaD
Erlotinib—PIP4K2C—testis—hematologic cancer	0.00035	0.00905	CbGeAlD
Erlotinib—SLK—bone marrow—hematologic cancer	0.000349	0.00901	CbGeAlD
Erlotinib—ORM1—hematopoietic system—hematologic cancer	0.000343	0.00886	CbGeAlD
Erlotinib—CYP3A4—Prednisone—hematologic cancer	0.000341	0.000874	CbGbCtD
Erlotinib—CYP2D6—Dexamethasone—hematologic cancer	0.000335	0.000858	CbGbCtD
Erlotinib—ULK3—testis—hematologic cancer	0.000335	0.00864	CbGeAlD
Erlotinib—MKNK1—lung—hematologic cancer	0.000334	0.00862	CbGeAlD
Erlotinib—SLCO2B1—hematopoietic system—hematologic cancer	0.000329	0.00849	CbGeAlD
Erlotinib—TNK1—lymph node—hematologic cancer	0.000327	0.00845	CbGeAlD
Erlotinib—ABL1—hematopoietic system—hematologic cancer	0.000326	0.00842	CbGeAlD
Erlotinib—CYP3A4—Irinotecan—hematologic cancer	0.000323	0.000828	CbGbCtD
Erlotinib—SLK—lung—hematologic cancer	0.000316	0.00816	CbGeAlD
Erlotinib—MKNK1—testis—hematologic cancer	0.000315	0.00813	CbGeAlD
Erlotinib—STK10—blood—hematologic cancer	0.000314	0.0081	CbGeAlD
Erlotinib—STK10—bone marrow—hematologic cancer	0.000303	0.00783	CbGeAlD
Erlotinib—Vandetanib—RET—hematologic cancer	0.0003	0.104	CrCbGaD
Erlotinib—SLK—testis—hematologic cancer	0.000298	0.0077	CbGeAlD
Erlotinib—UGT1A1—blood—hematologic cancer	0.000296	0.00765	CbGeAlD
Erlotinib—ABCB1—Doxorubicin—hematologic cancer	0.000295	0.000755	CbGbCtD
Erlotinib—CYP3A4—Vinblastine—hematologic cancer	0.000287	0.000737	CbGbCtD
Erlotinib—ABCB1—Methotrexate—hematologic cancer	0.000286	0.000732	CbGbCtD
Erlotinib—CYP3A4—Vincristine—hematologic cancer	0.000283	0.000724	CbGbCtD
Erlotinib—FLT3—lymph node—hematologic cancer	0.000281	0.00726	CbGeAlD
Erlotinib—MAP2K5—blood—hematologic cancer	0.00028	0.00723	CbGeAlD
Erlotinib—CYP2D6—Doxorubicin—hematologic cancer	0.000278	0.000712	CbGbCtD
Erlotinib—CYP1B1—hematopoietic system—hematologic cancer	0.000276	0.00713	CbGeAlD
Erlotinib—STK10—lung—hematologic cancer	0.000275	0.0071	CbGeAlD
Erlotinib—ABL2—lymph node—hematologic cancer	0.000268	0.00693	CbGeAlD
Erlotinib—EGFR—lymph node—hematologic cancer	0.000262	0.00677	CbGeAlD
Erlotinib—STK10—testis—hematologic cancer	0.000259	0.0067	CbGeAlD
Erlotinib—CYP3A4—Etoposide—hematologic cancer	0.000259	0.000664	CbGbCtD
Erlotinib—PIP4K2C—lymph node—hematologic cancer	0.000254	0.00656	CbGeAlD
Erlotinib—ABL1—Topotecan—Irinotecan—hematologic cancer	0.000253	0.169	CbGdCrCtD
Erlotinib—ABL1—gonad—hematologic cancer	0.000248	0.0064	CbGeAlD
Erlotinib—MAP2K5—lung—hematologic cancer	0.000245	0.00634	CbGeAlD
Erlotinib—ULK3—lymph node—hematologic cancer	0.000243	0.00626	CbGeAlD
Erlotinib—MAP2K5—testis—hematologic cancer	0.000232	0.00598	CbGeAlD
Erlotinib—MKNK1—lymph node—hematologic cancer	0.000228	0.00589	CbGeAlD
Erlotinib—ORM1—blood—hematologic cancer	0.000227	0.00587	CbGeAlD
Erlotinib—ORM1—bone marrow—hematologic cancer	0.00022	0.00568	CbGeAlD
Erlotinib—SLK—lymph node—hematologic cancer	0.000216	0.00558	CbGeAlD
Erlotinib—ABL1—blood—hematologic cancer	0.000216	0.00558	CbGeAlD
Erlotinib—CYP3A4—Dexamethasone—hematologic cancer	0.000213	0.000546	CbGbCtD
Erlotinib—CYP2C8—hematopoietic system—hematologic cancer	0.000211	0.00546	CbGeAlD
Erlotinib—CYP1B1—gonad—hematologic cancer	0.00021	0.00542	CbGeAlD
Erlotinib—ABL1—bone marrow—hematologic cancer	0.000209	0.0054	CbGeAlD
Erlotinib—Vandetanib—PDGFRB—hematologic cancer	0.000208	0.072	CrCbGaD
Erlotinib—ORM1—lung—hematologic cancer	0.000199	0.00515	CbGeAlD
Erlotinib—CYP1A2—hematopoietic system—hematologic cancer	0.000198	0.00511	CbGeAlD
Erlotinib—CYP1A1—hematopoietic system—hematologic cancer	0.000195	0.00504	CbGeAlD
Erlotinib—SLCO2B1—lung—hematologic cancer	0.000191	0.00493	CbGeAlD
Erlotinib—CYP3A5—hematopoietic system—hematologic cancer	0.000191	0.00493	CbGeAlD
Erlotinib—ABL1—lung—hematologic cancer	0.000189	0.00489	CbGeAlD
Erlotinib—STK10—lymph node—hematologic cancer	0.000188	0.00485	CbGeAlD
Erlotinib—Vandetanib—ABL1—hematologic cancer	0.000185	0.0642	CrCbGaD
Erlotinib—CYP1B1—blood—hematologic cancer	0.000183	0.00472	CbGeAlD
Erlotinib—SLCO2B1—testis—hematologic cancer	0.00018	0.00465	CbGeAlD
Erlotinib—ABL1—testis—hematologic cancer	0.000179	0.00461	CbGeAlD
Erlotinib—CYP3A4—Doxorubicin—hematologic cancer	0.000177	0.000453	CbGbCtD
Erlotinib—ABL1—Doxorubicin—Daunorubicin—hematologic cancer	0.000171	0.114	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Daunorubicin—hematologic cancer	0.000171	0.114	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Daunorubicin—hematologic cancer	0.000171	0.114	CbGdCrCtD
Erlotinib—MAP2K5—lymph node—hematologic cancer	0.000168	0.00434	CbGeAlD
Erlotinib—Vandetanib—SRC—hematologic cancer	0.000168	0.0581	CrCbGaD
Erlotinib—ALB—testis—hematologic cancer	0.000165	0.00426	CbGeAlD
Erlotinib—CYP1B1—lung—hematologic cancer	0.00016	0.00414	CbGeAlD
Erlotinib—CYP1B1—testis—hematologic cancer	0.000151	0.00391	CbGeAlD
Erlotinib—CYP3A4—hematopoietic system—hematologic cancer	0.000143	0.0037	CbGeAlD
Erlotinib—CYP2D6—hematopoietic system—hematologic cancer	0.000141	0.00364	CbGeAlD
Erlotinib—CYP2C8—blood—hematologic cancer	0.00014	0.00362	CbGeAlD
Erlotinib—ORM1—lymph node—hematologic cancer	0.000136	0.00352	CbGeAlD
Erlotinib—ABCG2—blood—hematologic cancer	0.000136	0.00352	CbGeAlD
Erlotinib—Vandetanib—VEGFA—hematologic cancer	0.000134	0.0463	CrCbGaD
Erlotinib—ABCG2—bone marrow—hematologic cancer	0.000132	0.0034	CbGeAlD
Erlotinib—CYP1A2—blood—hematologic cancer	0.000131	0.00339	CbGeAlD
Erlotinib—SLCO2B1—lymph node—hematologic cancer	0.000131	0.00337	CbGeAlD
Erlotinib—ABL1—Daunorubicin—Idarubicin—hematologic cancer	0.00013	0.0865	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Idarubicin—hematologic cancer	0.00013	0.0865	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Idarubicin—hematologic cancer	0.00013	0.0865	CbGdCrCtD
Erlotinib—ABL1—lymph node—hematologic cancer	0.000129	0.00334	CbGeAlD
Erlotinib—CYP1A1—blood—hematologic cancer	0.000129	0.00334	CbGeAlD
Erlotinib—CYP3A5—blood—hematologic cancer	0.000126	0.00327	CbGeAlD
Erlotinib—ALB—lymph node—hematologic cancer	0.00012	0.00309	CbGeAlD
Erlotinib—ABCG2—lung—hematologic cancer	0.000119	0.00308	CbGeAlD
Erlotinib—CYP2C8—testis—hematologic cancer	0.000116	0.00299	CbGeAlD
Erlotinib—CYP1A2—lung—hematologic cancer	0.000115	0.00297	CbGeAlD
Erlotinib—CYP1A1—lung—hematologic cancer	0.000113	0.00293	CbGeAlD
Erlotinib—ABCG2—testis—hematologic cancer	0.000113	0.00291	CbGeAlD
Erlotinib—CYP3A5—lung—hematologic cancer	0.000111	0.00286	CbGeAlD
Erlotinib—CYP1B1—lymph node—hematologic cancer	0.00011	0.00283	CbGeAlD
Erlotinib—ABCB1—hematopoietic system—hematologic cancer	0.000101	0.00262	CbGeAlD
Erlotinib—CYP3A4—blood—hematologic cancer	9.49e-05	0.00245	CbGeAlD
Erlotinib—CYP2D6—blood—hematologic cancer	9.34e-05	0.00241	CbGeAlD
Erlotinib—Vandetanib—ABCG2—hematologic cancer	8.23e-05	0.0285	CrCbGaD
Erlotinib—ABCG2—lymph node—hematologic cancer	8.17e-05	0.00211	CbGeAlD
Erlotinib—Gefitinib—ABCG2—hematologic cancer	7.82e-05	0.0271	CrCbGaD
Erlotinib—CYP1A1—lymph node—hematologic cancer	7.75e-05	0.002	CbGeAlD
Erlotinib—CYP2D6—testis—hematologic cancer	7.72e-05	0.00199	CbGeAlD
Erlotinib—ABCB1—gonad—hematologic cancer	7.71e-05	0.00199	CbGeAlD
Erlotinib—ABCB1—blood—hematologic cancer	6.72e-05	0.00173	CbGeAlD
Erlotinib—ABCB1—bone marrow—hematologic cancer	6.5e-05	0.00168	CbGeAlD
Erlotinib—ABL1—Doxorubicin—Epirubicin—hematologic cancer	5.95e-05	0.0397	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—hematologic cancer	5.95e-05	0.0397	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Epirubicin—hematologic cancer	5.95e-05	0.0397	CbGdCrCtD
Erlotinib—ABCB1—lung—hematologic cancer	5.89e-05	0.00152	CbGeAlD
Erlotinib—ABCB1—testis—hematologic cancer	5.56e-05	0.00143	CbGeAlD
Erlotinib—ABL1—Idarubicin—Doxorubicin—hematologic cancer	5.51e-05	0.0367	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—hematologic cancer	5.51e-05	0.0367	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—hematologic cancer	5.51e-05	0.0367	CbGdCrCtD
Erlotinib—ABCB1—lymph node—hematologic cancer	4.03e-05	0.00104	CbGeAlD
Erlotinib—Vandetanib—ALB—hematologic cancer	3.59e-05	0.0124	CrCbGaD
Erlotinib—Gefitinib—ALB—hematologic cancer	3.41e-05	0.0118	CrCbGaD
Erlotinib—Gefitinib—ABCB1—hematologic cancer	3.25e-05	0.0113	CrCbGaD
Erlotinib—Epistaxis—Doxorubicin—hematologic cancer	1.04e-05	8.97e-05	CcSEcCtD
Erlotinib—Vomiting—Mitoxantrone—hematologic cancer	1.04e-05	8.94e-05	CcSEcCtD
Erlotinib—Vomiting—Irinotecan—hematologic cancer	1.04e-05	8.94e-05	CcSEcCtD
Erlotinib—Nausea—Alitretinoin—hematologic cancer	1.03e-05	8.9e-05	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—hematologic cancer	1.03e-05	8.88e-05	CcSEcCtD
Erlotinib—Rash—Irinotecan—hematologic cancer	1.03e-05	8.86e-05	CcSEcCtD
Erlotinib—Rash—Mitoxantrone—hematologic cancer	1.03e-05	8.86e-05	CcSEcCtD
Erlotinib—Dermatitis—Mitoxantrone—hematologic cancer	1.03e-05	8.85e-05	CcSEcCtD
Erlotinib—Dermatitis—Irinotecan—hematologic cancer	1.03e-05	8.85e-05	CcSEcCtD
Erlotinib—Chills—Methotrexate—hematologic cancer	1.03e-05	8.84e-05	CcSEcCtD
Erlotinib—Headache—Irinotecan—hematologic cancer	1.02e-05	8.81e-05	CcSEcCtD
Erlotinib—Headache—Mitoxantrone—hematologic cancer	1.02e-05	8.81e-05	CcSEcCtD
Erlotinib—Nausea—Ifosfamide—hematologic cancer	1.02e-05	8.79e-05	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Betamethasone—hematologic cancer	1.02e-05	8.77e-05	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	1.02e-05	8.77e-05	CcSEcCtD
Erlotinib—Arthralgia—Prednisone—hematologic cancer	1.02e-05	8.74e-05	CcSEcCtD
Erlotinib—Myalgia—Prednisone—hematologic cancer	1.02e-05	8.74e-05	CcSEcCtD
Erlotinib—Diarrhoea—Cisplatin—hematologic cancer	1.01e-05	8.73e-05	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—hematologic cancer	1.01e-05	8.72e-05	CcSEcCtD
Erlotinib—Anxiety—Prednisone—hematologic cancer	1.01e-05	8.71e-05	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—hematologic cancer	1.01e-05	8.71e-05	CcSEcCtD
Erlotinib—Vomiting—Gemcitabine—hematologic cancer	1.01e-05	8.71e-05	CcSEcCtD
Erlotinib—Insomnia—Dexamethasone—hematologic cancer	1.01e-05	8.7e-05	CcSEcCtD
Erlotinib—Insomnia—Betamethasone—hematologic cancer	1.01e-05	8.7e-05	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.01e-05	8.68e-05	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—hematologic cancer	1e-05	8.64e-05	CcSEcCtD
Erlotinib—Rash—Gemcitabine—hematologic cancer	1e-05	8.63e-05	CcSEcCtD
Erlotinib—Dermatitis—Gemcitabine—hematologic cancer	1e-05	8.63e-05	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—hematologic cancer	1e-05	8.62e-05	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—hematologic cancer	9.97e-06	8.58e-05	CcSEcCtD
Erlotinib—Erythema—Methotrexate—hematologic cancer	9.97e-06	8.58e-05	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—hematologic cancer	9.97e-06	8.58e-05	CcSEcCtD
Erlotinib—Headache—Gemcitabine—hematologic cancer	9.96e-06	8.58e-05	CcSEcCtD
Erlotinib—Nausea—Vincristine—hematologic cancer	9.96e-06	8.57e-05	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—hematologic cancer	9.92e-06	8.54e-05	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—hematologic cancer	9.92e-06	8.54e-05	CcSEcCtD
Erlotinib—Dyspepsia—Dexamethasone—hematologic cancer	9.84e-06	8.47e-05	CcSEcCtD
Erlotinib—Dyspepsia—Betamethasone—hematologic cancer	9.84e-06	8.47e-05	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—hematologic cancer	9.79e-06	8.43e-05	CcSEcCtD
Erlotinib—Asthenia—Etoposide—hematologic cancer	9.74e-06	8.39e-05	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—hematologic cancer	9.74e-06	8.39e-05	CcSEcCtD
Erlotinib—Body temperature increased—Triamcinolone—hematologic cancer	9.74e-06	8.38e-05	CcSEcCtD
Erlotinib—Oedema—Prednisone—hematologic cancer	9.73e-06	8.38e-05	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—hematologic cancer	9.72e-06	8.37e-05	CcSEcCtD
Erlotinib—Decreased appetite—Dexamethasone—hematologic cancer	9.72e-06	8.36e-05	CcSEcCtD
Erlotinib—Decreased appetite—Betamethasone—hematologic cancer	9.72e-06	8.36e-05	CcSEcCtD
Erlotinib—Nausea—Irinotecan—hematologic cancer	9.7e-06	8.35e-05	CcSEcCtD
Erlotinib—Nausea—Mitoxantrone—hematologic cancer	9.7e-06	8.35e-05	CcSEcCtD
Erlotinib—Infection—Prednisone—hematologic cancer	9.67e-06	8.32e-05	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—hematologic cancer	9.66e-06	8.31e-05	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	9.65e-06	8.31e-05	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Betamethasone—hematologic cancer	9.65e-06	8.31e-05	CcSEcCtD
Erlotinib—Back pain—Methotrexate—hematologic cancer	9.64e-06	8.3e-05	CcSEcCtD
Erlotinib—Fatigue—Dexamethasone—hematologic cancer	9.64e-06	8.3e-05	CcSEcCtD
Erlotinib—Fatigue—Betamethasone—hematologic cancer	9.64e-06	8.3e-05	CcSEcCtD
Erlotinib—Chills—Epirubicin—hematologic cancer	9.62e-06	8.28e-05	CcSEcCtD
Erlotinib—Pruritus—Etoposide—hematologic cancer	9.61e-06	8.27e-05	CcSEcCtD
Erlotinib—Shock—Prednisone—hematologic cancer	9.58e-06	8.24e-05	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—hematologic cancer	9.57e-06	8.24e-05	CcSEcCtD
Erlotinib—Pain—Betamethasone—hematologic cancer	9.56e-06	8.23e-05	CcSEcCtD
Erlotinib—Pain—Dexamethasone—hematologic cancer	9.56e-06	8.23e-05	CcSEcCtD
Erlotinib—Nervous system disorder—Prednisone—hematologic cancer	9.55e-06	8.22e-05	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—hematologic cancer	9.47e-06	8.15e-05	CcSEcCtD
Erlotinib—Skin disorder—Prednisone—hematologic cancer	9.46e-06	8.14e-05	CcSEcCtD
Erlotinib—Nausea—Gemcitabine—hematologic cancer	9.45e-06	8.13e-05	CcSEcCtD
Erlotinib—Vomiting—Cisplatin—hematologic cancer	9.43e-06	8.11e-05	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—hematologic cancer	9.39e-06	8.08e-05	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—hematologic cancer	9.38e-06	8.07e-05	CcSEcCtD
Erlotinib—Rash—Cisplatin—hematologic cancer	9.35e-06	8.05e-05	CcSEcCtD
Erlotinib—Dermatitis—Cisplatin—hematologic cancer	9.34e-06	8.04e-05	CcSEcCtD
Erlotinib—Erythema—Epirubicin—hematologic cancer	9.33e-06	8.03e-05	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—hematologic cancer	9.33e-06	8.03e-05	CcSEcCtD
Erlotinib—Diarrhoea—Etoposide—hematologic cancer	9.29e-06	8e-05	CcSEcCtD
Erlotinib—Anorexia—Prednisone—hematologic cancer	9.28e-06	7.99e-05	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—hematologic cancer	9.27e-06	7.98e-05	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—hematologic cancer	9.19e-06	7.91e-05	CcSEcCtD
Erlotinib—Gastrointestinal pain—Betamethasone—hematologic cancer	9.14e-06	7.87e-05	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dexamethasone—hematologic cancer	9.14e-06	7.87e-05	CcSEcCtD
Erlotinib—Back pain—Epirubicin—hematologic cancer	9.02e-06	7.77e-05	CcSEcCtD
Erlotinib—Dizziness—Etoposide—hematologic cancer	8.98e-06	7.73e-05	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—hematologic cancer	8.94e-06	7.69e-05	CcSEcCtD
Erlotinib—Chills—Doxorubicin—hematologic cancer	8.9e-06	7.66e-05	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Prednisone—hematologic cancer	8.87e-06	7.63e-05	CcSEcCtD
Erlotinib—Dizziness—Prednisolone—hematologic cancer	8.86e-06	7.63e-05	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—hematologic cancer	8.86e-06	7.62e-05	CcSEcCtD
Erlotinib—Asthenia—Triamcinolone—hematologic cancer	8.84e-06	7.61e-05	CcSEcCtD
Erlotinib—Abdominal pain—Dexamethasone—hematologic cancer	8.84e-06	7.61e-05	CcSEcCtD
Erlotinib—Abdominal pain—Betamethasone—hematologic cancer	8.84e-06	7.61e-05	CcSEcCtD
Erlotinib—Body temperature increased—Dexamethasone—hematologic cancer	8.84e-06	7.61e-05	CcSEcCtD
Erlotinib—Body temperature increased—Betamethasone—hematologic cancer	8.84e-06	7.61e-05	CcSEcCtD
Erlotinib—Nausea—Cisplatin—hematologic cancer	8.81e-06	7.58e-05	CcSEcCtD
Erlotinib—Insomnia—Prednisone—hematologic cancer	8.8e-06	7.58e-05	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—hematologic cancer	8.76e-06	7.54e-05	CcSEcCtD
Erlotinib—Pruritus—Triamcinolone—hematologic cancer	8.72e-06	7.5e-05	CcSEcCtD
Erlotinib—Cough—Methotrexate—hematologic cancer	8.7e-06	7.49e-05	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—hematologic cancer	8.69e-06	7.48e-05	CcSEcCtD
Erlotinib—Vomiting—Etoposide—hematologic cancer	8.64e-06	7.43e-05	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—hematologic cancer	8.63e-06	7.43e-05	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—hematologic cancer	8.63e-06	7.43e-05	CcSEcCtD
Erlotinib—Dyspepsia—Prednisone—hematologic cancer	8.57e-06	7.38e-05	CcSEcCtD
Erlotinib—Rash—Etoposide—hematologic cancer	8.56e-06	7.37e-05	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—hematologic cancer	8.56e-06	7.36e-05	CcSEcCtD
Erlotinib—Headache—Etoposide—hematologic cancer	8.51e-06	7.32e-05	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—hematologic cancer	8.51e-06	7.32e-05	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—hematologic cancer	8.49e-06	7.31e-05	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—hematologic cancer	8.49e-06	7.31e-05	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—hematologic cancer	8.49e-06	7.31e-05	CcSEcCtD
Erlotinib—Decreased appetite—Prednisone—hematologic cancer	8.46e-06	7.28e-05	CcSEcCtD
Erlotinib—Rash—Prednisolone—hematologic cancer	8.45e-06	7.27e-05	CcSEcCtD
Erlotinib—Dermatitis—Prednisolone—hematologic cancer	8.44e-06	7.26e-05	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	8.43e-06	7.26e-05	CcSEcCtD
Erlotinib—Fatigue—Prednisone—hematologic cancer	8.39e-06	7.22e-05	CcSEcCtD
Erlotinib—Headache—Prednisolone—hematologic cancer	8.39e-06	7.22e-05	CcSEcCtD
Erlotinib—Syncope—Epirubicin—hematologic cancer	8.37e-06	7.2e-05	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—hematologic cancer	8.35e-06	7.19e-05	CcSEcCtD
Erlotinib—Constipation—Prednisone—hematologic cancer	8.32e-06	7.17e-05	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—hematologic cancer	8.2e-06	7.06e-05	CcSEcCtD
Erlotinib—Dizziness—Triamcinolone—hematologic cancer	8.15e-06	7.01e-05	CcSEcCtD
Erlotinib—Cough—Epirubicin—hematologic cancer	8.14e-06	7.01e-05	CcSEcCtD
Erlotinib—Infection—Methotrexate—hematologic cancer	8.08e-06	6.96e-05	CcSEcCtD
Erlotinib—Nausea—Etoposide—hematologic cancer	8.07e-06	6.94e-05	CcSEcCtD
Erlotinib—Asthenia—Dexamethasone—hematologic cancer	8.02e-06	6.9e-05	CcSEcCtD
Erlotinib—Asthenia—Betamethasone—hematologic cancer	8.02e-06	6.9e-05	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—hematologic cancer	7.98e-06	6.87e-05	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—hematologic cancer	7.97e-06	6.86e-05	CcSEcCtD
Erlotinib—Gastrointestinal pain—Prednisone—hematologic cancer	7.96e-06	6.85e-05	CcSEcCtD
Erlotinib—Nausea—Prednisolone—hematologic cancer	7.96e-06	6.85e-05	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—hematologic cancer	7.94e-06	6.84e-05	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—hematologic cancer	7.94e-06	6.84e-05	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—hematologic cancer	7.94e-06	6.84e-05	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—hematologic cancer	7.91e-06	6.81e-05	CcSEcCtD
Erlotinib—Pruritus—Dexamethasone—hematologic cancer	7.91e-06	6.81e-05	CcSEcCtD
Erlotinib—Pruritus—Betamethasone—hematologic cancer	7.91e-06	6.81e-05	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—hematologic cancer	7.9e-06	6.8e-05	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	7.89e-06	6.79e-05	CcSEcCtD
Erlotinib—Vomiting—Triamcinolone—hematologic cancer	7.83e-06	6.74e-05	CcSEcCtD
Erlotinib—Rash—Triamcinolone—hematologic cancer	7.77e-06	6.69e-05	CcSEcCtD
Erlotinib—Dermatitis—Triamcinolone—hematologic cancer	7.76e-06	6.68e-05	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—hematologic cancer	7.75e-06	6.68e-05	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—hematologic cancer	7.74e-06	6.66e-05	CcSEcCtD
Erlotinib—Headache—Triamcinolone—hematologic cancer	7.72e-06	6.64e-05	CcSEcCtD
Erlotinib—Abdominal pain—Prednisone—hematologic cancer	7.7e-06	6.62e-05	CcSEcCtD
Erlotinib—Body temperature increased—Prednisone—hematologic cancer	7.7e-06	6.62e-05	CcSEcCtD
Erlotinib—Diarrhoea—Betamethasone—hematologic cancer	7.65e-06	6.58e-05	CcSEcCtD
Erlotinib—Diarrhoea—Dexamethasone—hematologic cancer	7.65e-06	6.58e-05	CcSEcCtD
Erlotinib—Oedema—Epirubicin—hematologic cancer	7.61e-06	6.55e-05	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—hematologic cancer	7.59e-06	6.53e-05	CcSEcCtD
Erlotinib—Infection—Epirubicin—hematologic cancer	7.56e-06	6.51e-05	CcSEcCtD
Erlotinib—Cough—Doxorubicin—hematologic cancer	7.53e-06	6.48e-05	CcSEcCtD
Erlotinib—Shock—Epirubicin—hematologic cancer	7.49e-06	6.45e-05	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—hematologic cancer	7.47e-06	6.43e-05	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—hematologic cancer	7.45e-06	6.42e-05	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	7.41e-06	6.38e-05	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—hematologic cancer	7.4e-06	6.37e-05	CcSEcCtD
Erlotinib—Dizziness—Dexamethasone—hematologic cancer	7.39e-06	6.36e-05	CcSEcCtD
Erlotinib—Dizziness—Betamethasone—hematologic cancer	7.39e-06	6.36e-05	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—hematologic cancer	7.36e-06	6.33e-05	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—hematologic cancer	7.35e-06	6.33e-05	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—hematologic cancer	7.35e-06	6.33e-05	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—hematologic cancer	7.35e-06	6.33e-05	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—hematologic cancer	7.32e-06	6.3e-05	CcSEcCtD
Erlotinib—Nausea—Triamcinolone—hematologic cancer	7.32e-06	6.3e-05	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	7.3e-06	6.28e-05	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—hematologic cancer	7.26e-06	6.25e-05	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—hematologic cancer	7.25e-06	6.24e-05	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—hematologic cancer	7.16e-06	6.16e-05	CcSEcCtD
Erlotinib—Vomiting—Dexamethasone—hematologic cancer	7.11e-06	6.12e-05	CcSEcCtD
Erlotinib—Vomiting—Betamethasone—hematologic cancer	7.11e-06	6.12e-05	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—hematologic cancer	7.07e-06	6.09e-05	CcSEcCtD
Erlotinib—Rash—Betamethasone—hematologic cancer	7.05e-06	6.07e-05	CcSEcCtD
Erlotinib—Rash—Dexamethasone—hematologic cancer	7.05e-06	6.07e-05	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—hematologic cancer	7.04e-06	6.06e-05	CcSEcCtD
Erlotinib—Dermatitis—Dexamethasone—hematologic cancer	7.04e-06	6.06e-05	CcSEcCtD
Erlotinib—Dermatitis—Betamethasone—hematologic cancer	7.04e-06	6.06e-05	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	7.02e-06	6.05e-05	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—hematologic cancer	7.01e-06	6.04e-05	CcSEcCtD
Erlotinib—Headache—Betamethasone—hematologic cancer	7e-06	6.03e-05	CcSEcCtD
Erlotinib—Headache—Dexamethasone—hematologic cancer	7e-06	6.03e-05	CcSEcCtD
Erlotinib—Infection—Doxorubicin—hematologic cancer	7e-06	6.02e-05	CcSEcCtD
Erlotinib—Asthenia—Prednisone—hematologic cancer	6.98e-06	6.01e-05	CcSEcCtD
Erlotinib—Pain—Methotrexate—hematologic cancer	6.96e-06	5.99e-05	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	6.94e-06	5.97e-05	CcSEcCtD
Erlotinib—Shock—Doxorubicin—hematologic cancer	6.93e-06	5.97e-05	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—hematologic cancer	6.91e-06	5.95e-05	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—hematologic cancer	6.9e-06	5.94e-05	CcSEcCtD
Erlotinib—Pruritus—Prednisone—hematologic cancer	6.89e-06	5.93e-05	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—hematologic cancer	6.89e-06	5.93e-05	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—hematologic cancer	6.84e-06	5.89e-05	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—hematologic cancer	6.79e-06	5.84e-05	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—hematologic cancer	6.71e-06	5.78e-05	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—hematologic cancer	6.7e-06	5.77e-05	CcSEcCtD
Erlotinib—Diarrhoea—Prednisone—hematologic cancer	6.66e-06	5.73e-05	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—hematologic cancer	6.65e-06	5.73e-05	CcSEcCtD
Erlotinib—Nausea—Dexamethasone—hematologic cancer	6.64e-06	5.72e-05	CcSEcCtD
Erlotinib—Nausea—Betamethasone—hematologic cancer	6.64e-06	5.72e-05	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—hematologic cancer	6.62e-06	5.7e-05	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.57e-06	5.66e-05	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—hematologic cancer	6.56e-06	5.65e-05	CcSEcCtD
Erlotinib—Constipation—Epirubicin—hematologic cancer	6.51e-06	5.6e-05	CcSEcCtD
Erlotinib—Pain—Epirubicin—hematologic cancer	6.51e-06	5.6e-05	CcSEcCtD
Erlotinib—Dizziness—Prednisone—hematologic cancer	6.44e-06	5.54e-05	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—hematologic cancer	6.43e-06	5.54e-05	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—hematologic cancer	6.43e-06	5.54e-05	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	6.42e-06	5.52e-05	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—hematologic cancer	6.37e-06	5.48e-05	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—hematologic cancer	6.28e-06	5.41e-05	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—hematologic cancer	6.23e-06	5.36e-05	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—hematologic cancer	6.2e-06	5.34e-05	CcSEcCtD
Erlotinib—Vomiting—Prednisone—hematologic cancer	6.19e-06	5.33e-05	CcSEcCtD
Erlotinib—Rash—Prednisone—hematologic cancer	6.14e-06	5.28e-05	CcSEcCtD
Erlotinib—Dermatitis—Prednisone—hematologic cancer	6.13e-06	5.28e-05	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—hematologic cancer	6.12e-06	5.27e-05	CcSEcCtD
Erlotinib—Headache—Prednisone—hematologic cancer	6.1e-06	5.25e-05	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.08e-06	5.24e-05	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—hematologic cancer	6.07e-06	5.23e-05	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—hematologic cancer	6.02e-06	5.19e-05	CcSEcCtD
Erlotinib—Pain—Doxorubicin—hematologic cancer	6.02e-06	5.19e-05	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—hematologic cancer	6.02e-06	5.18e-05	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—hematologic cancer	6.02e-06	5.18e-05	CcSEcCtD
Erlotinib—Asthenia—Methotrexate—hematologic cancer	5.84e-06	5.02e-05	CcSEcCtD
Erlotinib—Nausea—Prednisone—hematologic cancer	5.78e-06	4.98e-05	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.76e-06	4.96e-05	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—hematologic cancer	5.76e-06	4.95e-05	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—hematologic cancer	5.57e-06	4.79e-05	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—hematologic cancer	5.57e-06	4.79e-05	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—hematologic cancer	5.57e-06	4.79e-05	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—hematologic cancer	5.46e-06	4.7e-05	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—hematologic cancer	5.39e-06	4.64e-05	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—hematologic cancer	5.38e-06	4.63e-05	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—hematologic cancer	5.21e-06	4.48e-05	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—hematologic cancer	5.17e-06	4.45e-05	CcSEcCtD
Erlotinib—Rash—Methotrexate—hematologic cancer	5.13e-06	4.42e-05	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—hematologic cancer	5.12e-06	4.41e-05	CcSEcCtD
Erlotinib—Headache—Methotrexate—hematologic cancer	5.1e-06	4.39e-05	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—hematologic cancer	5.05e-06	4.35e-05	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—hematologic cancer	5.03e-06	4.33e-05	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—hematologic cancer	4.98e-06	4.29e-05	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—hematologic cancer	4.84e-06	4.17e-05	CcSEcCtD
Erlotinib—Nausea—Methotrexate—hematologic cancer	4.83e-06	4.16e-05	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—hematologic cancer	4.82e-06	4.15e-05	CcSEcCtD
Erlotinib—Rash—Epirubicin—hematologic cancer	4.8e-06	4.13e-05	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—hematologic cancer	4.8e-06	4.13e-05	CcSEcCtD
Erlotinib—Headache—Epirubicin—hematologic cancer	4.77e-06	4.11e-05	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—hematologic cancer	4.66e-06	4.01e-05	CcSEcCtD
Erlotinib—Nausea—Epirubicin—hematologic cancer	4.52e-06	3.89e-05	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—hematologic cancer	4.48e-06	3.86e-05	CcSEcCtD
Erlotinib—Rash—Doxorubicin—hematologic cancer	4.44e-06	3.82e-05	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—hematologic cancer	4.44e-06	3.82e-05	CcSEcCtD
Erlotinib—Headache—Doxorubicin—hematologic cancer	4.41e-06	3.8e-05	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—hematologic cancer	4.18e-06	3.6e-05	CcSEcCtD
Erlotinib—CYP1A2—Metabolism—SDC1—hematologic cancer	6.25e-07	7.8e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.23e-07	7.78e-06	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—hematologic cancer	6.2e-07	7.74e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTPN11—hematologic cancer	6.17e-07	7.7e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.17e-07	7.7e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CD—hematologic cancer	6.16e-07	7.69e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.13e-07	7.65e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—EP300—hematologic cancer	6.13e-07	7.65e-06	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—hematologic cancer	6.11e-07	7.63e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—hematologic cancer	6.08e-07	7.59e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK3—hematologic cancer	6.03e-07	7.53e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCB1—hematologic cancer	6.03e-07	7.53e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK3—hematologic cancer	6.01e-07	7.51e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCB1—hematologic cancer	6e-07	7.49e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	5.99e-07	7.47e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—hematologic cancer	5.98e-07	7.46e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CREB1—hematologic cancer	5.98e-07	7.46e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.97e-07	7.45e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SRC—hematologic cancer	5.96e-07	7.44e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1A—hematologic cancer	5.95e-07	7.43e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—hematologic cancer	5.95e-07	7.42e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYCS—hematologic cancer	5.94e-07	7.41e-06	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—hematologic cancer	5.94e-07	7.41e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—hematologic cancer	5.94e-07	7.41e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CB—hematologic cancer	5.9e-07	7.37e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—hematologic cancer	5.9e-07	7.37e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	5.9e-07	7.36e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	5.89e-07	7.36e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NCOR1—hematologic cancer	5.86e-07	7.31e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—hematologic cancer	5.86e-07	7.31e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—hematologic cancer	5.86e-07	7.31e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL2—hematologic cancer	5.85e-07	7.3e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6R—hematologic cancer	5.83e-07	7.28e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NCOR1—hematologic cancer	5.82e-07	7.27e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—hematologic cancer	5.82e-07	7.27e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.82e-07	7.27e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.82e-07	7.27e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CREBBP—hematologic cancer	5.82e-07	7.27e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3R1—hematologic cancer	5.82e-07	7.26e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—hematologic cancer	5.78e-07	7.21e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—hematologic cancer	5.75e-07	7.18e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—hematologic cancer	5.74e-07	7.16e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.67e-07	7.08e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—EP300—hematologic cancer	5.66e-07	7.07e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—hematologic cancer	5.65e-07	7.05e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.64e-07	7.04e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAP2K1—hematologic cancer	5.56e-07	6.93e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—hematologic cancer	5.55e-07	6.93e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CD—hematologic cancer	5.52e-07	6.89e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—SRC—hematologic cancer	5.5e-07	6.87e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NUP98—hematologic cancer	5.5e-07	6.86e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK3—hematologic cancer	5.49e-07	6.86e-06	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—hematologic cancer	5.48e-07	6.84e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—hematologic cancer	5.47e-07	6.83e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—hematologic cancer	5.46e-07	6.82e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—hematologic cancer	5.42e-07	6.77e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—hematologic cancer	5.4e-07	6.74e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CB—hematologic cancer	5.37e-07	6.7e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.33e-07	6.66e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.33e-07	6.66e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CD44—hematologic cancer	5.32e-07	6.64e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NQO1—hematologic cancer	5.32e-07	6.64e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—hematologic cancer	5.31e-07	6.63e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—hematologic cancer	5.31e-07	6.63e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NUP214—hematologic cancer	5.3e-07	6.61e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—hematologic cancer	5.3e-07	6.61e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—hematologic cancer	5.29e-07	6.6e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF2—hematologic cancer	5.28e-07	6.6e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—hematologic cancer	5.23e-07	6.53e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—EP300—hematologic cancer	5.22e-07	6.51e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3R1—hematologic cancer	5.21e-07	6.51e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.2e-07	6.5e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.19e-07	6.48e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTR—hematologic cancer	5.19e-07	6.48e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—hematologic cancer	5.18e-07	6.46e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—hematologic cancer	5.15e-07	6.43e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NCOR1—hematologic cancer	5.1e-07	6.37e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—hematologic cancer	5.1e-07	6.37e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—hematologic cancer	5.1e-07	6.37e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO2—hematologic cancer	5.09e-07	6.35e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK3—hematologic cancer	5.07e-07	6.33e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JAK2—hematologic cancer	5.06e-07	6.32e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—hematologic cancer	5.06e-07	6.31e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYCS—hematologic cancer	5.03e-07	6.28e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CG—hematologic cancer	5.02e-07	6.27e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	5e-07	6.24e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—hematologic cancer	4.98e-07	6.22e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.98e-07	6.21e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—hematologic cancer	4.96e-07	6.2e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.95e-07	6.18e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MDM2—hematologic cancer	4.94e-07	6.17e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—hematologic cancer	4.94e-07	6.16e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.94e-07	6.16e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—hematologic cancer	4.93e-07	6.16e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—hematologic cancer	4.92e-07	6.14e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—hematologic cancer	4.91e-07	6.13e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—EP300—hematologic cancer	4.86e-07	6.07e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—hematologic cancer	4.84e-07	6.04e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SDC1—hematologic cancer	4.82e-07	6.02e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—hematologic cancer	4.82e-07	6.02e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MTOR—hematologic cancer	4.81e-07	6e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CB—hematologic cancer	4.81e-07	6e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.81e-07	6e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.81e-07	6e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CG—hematologic cancer	4.74e-07	5.92e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—hematologic cancer	4.7e-07	5.87e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CREBBP—hematologic cancer	4.66e-07	5.81e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—hematologic cancer	4.64e-07	5.79e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—hematologic cancer	4.61e-07	5.75e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—hematologic cancer	4.59e-07	5.73e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.56e-07	5.7e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—hematologic cancer	4.56e-07	5.69e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.54e-07	5.66e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—hematologic cancer	4.54e-07	5.66e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—hematologic cancer	4.51e-07	5.64e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—hematologic cancer	4.51e-07	5.63e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.5e-07	5.61e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—hematologic cancer	4.46e-07	5.57e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—hematologic cancer	4.43e-07	5.53e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—EP300—hematologic cancer	4.43e-07	5.52e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—hematologic cancer	4.42e-07	5.52e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—hematologic cancer	4.42e-07	5.51e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CD—hematologic cancer	4.41e-07	5.51e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CREBBP—hematologic cancer	4.4e-07	5.49e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—hematologic cancer	4.4e-07	5.49e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—hematologic cancer	4.36e-07	5.44e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CG—hematologic cancer	4.35e-07	5.43e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—hematologic cancer	4.34e-07	5.41e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CG—hematologic cancer	4.32e-07	5.4e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—hematologic cancer	4.31e-07	5.38e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JUN—hematologic cancer	4.3e-07	5.36e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.29e-07	5.35e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.25e-07	5.31e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—hematologic cancer	4.2e-07	5.24e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—hematologic cancer	4.2e-07	5.24e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—hematologic cancer	4.19e-07	5.23e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CD—hematologic cancer	4.17e-07	5.21e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3R1—hematologic cancer	4.17e-07	5.2e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1A—hematologic cancer	4.17e-07	5.2e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—hematologic cancer	4.16e-07	5.19e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—hematologic cancer	4.12e-07	5.14e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NQO1—hematologic cancer	4.1e-07	5.12e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CD44—hematologic cancer	4.1e-07	5.12e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—hematologic cancer	4.07e-07	5.09e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NCOR1—hematologic cancer	4.07e-07	5.09e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—hematologic cancer	4.07e-07	5.08e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK8—hematologic cancer	4.07e-07	5.08e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—hematologic cancer	4.06e-07	5.06e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CREBBP—hematologic cancer	4.03e-07	5.03e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—hematologic cancer	4.02e-07	5.01e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CREBBP—hematologic cancer	4.01e-07	5.01e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EP300—hematologic cancer	3.96e-07	4.95e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3R1—hematologic cancer	3.94e-07	4.92e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYCS—hematologic cancer	3.88e-07	4.85e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—hematologic cancer	3.87e-07	4.84e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—hematologic cancer	3.86e-07	4.82e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.86e-07	4.81e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SRC—hematologic cancer	3.85e-07	4.81e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CB—hematologic cancer	3.85e-07	4.8e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CD—hematologic cancer	3.82e-07	4.77e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CD—hematologic cancer	3.8e-07	4.75e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CG—hematologic cancer	3.79e-07	4.73e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—hematologic cancer	3.77e-07	4.71e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—hematologic cancer	3.75e-07	4.69e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—hematologic cancer	3.72e-07	4.64e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—hematologic cancer	3.71e-07	4.63e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—hematologic cancer	3.71e-07	4.63e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—hematologic cancer	3.71e-07	4.63e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CB—hematologic cancer	3.64e-07	4.54e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3R1—hematologic cancer	3.61e-07	4.51e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—hematologic cancer	3.6e-07	4.49e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—hematologic cancer	3.6e-07	4.49e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3R1—hematologic cancer	3.59e-07	4.48e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.57e-07	4.46e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK3—hematologic cancer	3.55e-07	4.43e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CREBBP—hematologic cancer	3.51e-07	4.39e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—hematologic cancer	3.45e-07	4.31e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—hematologic cancer	3.45e-07	4.3e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.42e-07	4.27e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—hematologic cancer	3.42e-07	4.27e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CB—hematologic cancer	3.33e-07	4.16e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.33e-07	4.16e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—hematologic cancer	3.33e-07	4.15e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CB—hematologic cancer	3.31e-07	4.14e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.31e-07	4.13e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—hematologic cancer	3.29e-07	4.11e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—hematologic cancer	3.27e-07	4.09e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.24e-07	4.04e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—hematologic cancer	3.19e-07	3.98e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.17e-07	3.96e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—EP300—hematologic cancer	3.17e-07	3.96e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—hematologic cancer	3.15e-07	3.93e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3R1—hematologic cancer	3.15e-07	3.93e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.14e-07	3.92e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.14e-07	3.92e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—hematologic cancer	3.14e-07	3.92e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.14e-07	3.92e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—hematologic cancer	3.1e-07	3.87e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CG—hematologic cancer	3.03e-07	3.78e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—EP300—hematologic cancer	3e-07	3.74e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.96e-07	3.7e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—hematologic cancer	2.94e-07	3.67e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—hematologic cancer	2.93e-07	3.66e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.9e-07	3.62e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—hematologic cancer	2.88e-07	3.6e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—hematologic cancer	2.86e-07	3.57e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—hematologic cancer	2.84e-07	3.54e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CREBBP—hematologic cancer	2.8e-07	3.5e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.78e-07	3.47e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—EP300—hematologic cancer	2.75e-07	3.43e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.74e-07	3.42e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—EP300—hematologic cancer	2.73e-07	3.41e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—hematologic cancer	2.71e-07	3.39e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—hematologic cancer	2.67e-07	3.34e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CD—hematologic cancer	2.66e-07	3.32e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—hematologic cancer	2.63e-07	3.28e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—hematologic cancer	2.6e-07	3.24e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3R1—hematologic cancer	2.51e-07	3.13e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—hematologic cancer	2.51e-07	3.13e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—hematologic cancer	2.4e-07	2.99e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—EP300—hematologic cancer	2.39e-07	2.99e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—hematologic cancer	2.36e-07	2.95e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—hematologic cancer	2.35e-07	2.93e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.33e-07	2.91e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CB—hematologic cancer	2.32e-07	2.89e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—EP300—hematologic cancer	2.25e-07	2.81e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—hematologic cancer	2.22e-07	2.77e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.16e-07	2.7e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.05e-07	2.56e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—hematologic cancer	2.03e-07	2.54e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—hematologic cancer	2.03e-07	2.53e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—hematologic cancer	2.02e-07	2.52e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—hematologic cancer	2e-07	2.5e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.94e-07	2.42e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—hematologic cancer	1.92e-07	2.39e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—EP300—hematologic cancer	1.91e-07	2.38e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—hematologic cancer	1.81e-07	2.26e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.79e-07	2.23e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.77e-07	2.21e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.67e-07	2.08e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—hematologic cancer	1.66e-07	2.07e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—hematologic cancer	1.65e-07	2.06e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—hematologic cancer	1.55e-07	1.93e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—EP300—hematologic cancer	1.47e-07	1.84e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—hematologic cancer	1.45e-07	1.81e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.41e-07	1.76e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—hematologic cancer	1.36e-07	1.7e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—hematologic cancer	1.15e-07	1.44e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.09e-07	1.36e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—hematologic cancer	8.91e-08	1.11e-06	CbGpPWpGaD
